Labs / Assays & in vitro testing
Priavoid
Düsseldorf, Germany · priavoid.com
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Priavoid develops orally available all-D-peptide therapeutics that target neurotoxic protein aggregation in neurodegenerative disorders. The company is based in Düsseldorf, Germany, and focuses on Alzheimer’s disease, synucleinopathies such as Parkinson’s disease and multiple system atrophy, tau-related disease, and amyotrophic lateral sclerosis.
They take quote requests by email.
What they offer
Drug discovery platform for all-D-peptide therapeutics
Identifies and designs tailored all-D-peptide compounds against toxic oligomers using mirror-image-phage-display technology and rational design.
Peptide optimization
Optimizes candidate peptides for efficacy, stability, and penetration of the blood-brain barrier and cell membranes.
Preclinical development
Advances platform-derived programs through preclinical development for neurodegenerative indications.
Clinical development
Advances lead program PRI-002 in Phase 2 clinical development for Alzheimer’s disease.
What they work on
- Modalities
- Peptide, Oligonucleotide
- Assays and studies
- mirror-image-phage-display technology, rational design, protein aggregation targeting, oligomer disassembly
- Therapeutic areas
- neurodegenerative disorders, Alzheimer’s disease, Parkinson’s disease, multiple system atrophy, amyotrophic lateral sclerosis
- Sites
- Düsseldorf, Germany
- Address
- Merowingerplatz 1 A 40225 Düsseldorf
- Founded
- 2004
Similar labs. Devsynthesis, MedChem Partners, Novalix, Sparx BIO
Found in a contract services directory. Listing built from priavoid.com. Work here? Claim this listing.